Skip to content
lifestyle.side.cr
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Capricor Therapeutics
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
September 17, 2026
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
August 24, 2026
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
August 10, 2026
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
July 30, 2026
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
July 29, 2026
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
July 27, 2026
Capricor Therapeutics to Present at Upcoming Investor Conferences
June 8, 2026
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
May 5, 2026
1
2
Next Page
→